Skip to main content

Advertisement

SpringerLink
Log in

Clinical significance of the ratio between the alpha 2 plasmin inhibitor–plasmin complex and the thrombin–antithrombin complex in advanced non-small cell lung cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aims of this study are to: (a) confirm the prognostic significance of the procoagulant molecules D dimer, thrombin–antithrombin complex (TAT), and plasmin-α2–plasmin inhibitor complex (PIC); (b) to evaluate hemostatic activation in patients with advanced non-small cell lung cancer (NSCLC); and (c) to delineate the relationships between markers of hemostasis and other clinical characteristics. In this study, a low PIC/TAT ratio and poor PS were significant independent negative prognostic factors for survival in patients with advanced NSCLC. The PIC/TAT ratio may become a surrogate marker for treatment with anticoagulants in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Antoniou D, Pavlakou G, Stathopoulos GP, et al. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer. 2006;53:205–10.

    Article  PubMed  Google Scholar 

  2. Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer. 2003;97:3044–52.

    Article  PubMed  CAS  Google Scholar 

  3. Gabazza EC, Taguchi O, Yamakami T, et al. Evaluating prethrombotic state in lung cancer using molecular markers. Chest. 1993;103:196–200.

    Article  PubMed  CAS  Google Scholar 

  4. Unsal E, Atalay F, Atikcan S, et al. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med. 2004;98:93–8.

    Article  PubMed  Google Scholar 

  5. Gordon SG. Cancer cell procoagulants and their role in malignant disease. Semin Thromb Hemost. 1992;18:424–33.

    Article  PubMed  CAS  Google Scholar 

  6. Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost. 1992;18:353–72.

    Article  PubMed  CAS  Google Scholar 

  7. Taguchi O, Gabazza EC, Yoshida M, et al. High plasma level of plasmin-alpha 2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer. Clin Chim Acta. 1996;244:69–81.

    Article  PubMed  CAS  Google Scholar 

  8. Seitz R, Heidtmann HH, Wolf M, et al. Prognostic impact of an activation of coagulation in lung cancer. Ann Oncol. 1997;8:781–4.

    Article  PubMed  CAS  Google Scholar 

  9. Watine J. Prognostic impact of an activation of coagulation in lung cancer. Ann Oncol. 1998;9:1255–6.

    Article  PubMed  CAS  Google Scholar 

  10. Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin–antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost. 1988;59:101–6.

    PubMed  CAS  Google Scholar 

  11. Mimuro J, Koike Y, Sumi Y, et al. Monoclonal antibodies to discrete regions in alpha 2-plasmin inhibitor. Blood. 1987;69:446–53.

    PubMed  CAS  Google Scholar 

  12. Goad KE, Gralnick HR. Coagulation disorders in cancer. Hematol Oncol Clin North Am. 1996;10:457–84.

    Article  PubMed  CAS  Google Scholar 

  13. Altiay G, Ciftci A, Demir M, et al. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol (R Coll Radiol). 2007;19:494–8.

    CAS  Google Scholar 

  14. Buccheri G, Ferrigno D, Ginardi C, et al. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer. 1997;33:50–5.

    Article  PubMed  CAS  Google Scholar 

  15. Langer F, Spath B, Haubold K, et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol. 2008;87:451–7.

    Article  PubMed  CAS  Google Scholar 

  16. Pavey SJ, Hawson GA, Marsh NA. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis. 2001;12:51–8.

    Article  PubMed  CAS  Google Scholar 

  17. Taguchi O, Gabazza EC, Yasui H, et al. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax. 1997;52:563–5.

    Article  PubMed  CAS  Google Scholar 

  18. Kwaan HC, Keer HN. Fibrinolysis and cancer. Semin Thromb Hemost. 1990;16:230–5.

    Article  PubMed  CAS  Google Scholar 

  19. Alessi MC, Chomiki N, Berthier R, et al. Detection of plasminogen activator inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization. Thromb Haemost. 1994;72:931–6.

    PubMed  CAS  Google Scholar 

  20. Madoiwa S, Komatsu N, Mimuro J, et al. Developmental expression of plasminogen activator inhibitor-1 associated with thrombopoietin-dependent megakaryocytic differentiation. Blood. 1999;94:475–82.

    PubMed  CAS  Google Scholar 

  21. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–9.

    Article  PubMed  CAS  Google Scholar 

  22. Levine MN, Lee AY, Kakkar AK. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost. 2003;1:1456–63.

    Article  PubMed  CAS  Google Scholar 

  23. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 2001;53:93–105.

    PubMed  CAS  Google Scholar 

  24. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial. N Engl J Med. 2000;342:1953–8.

    Article  PubMed  CAS  Google Scholar 

  25. Akl EA, Muti P, Schunemann HJ. Anticoagulation in patients with cancer: an overview of reviews. Pol Arch Med Wewn. 2008;118:183–93.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Syogoin-Kawaracho, Sakyo-Ku, Kyoto, 606-8507, Japan

    Katsuhiro Masago, Tadashi Mio, Yosuke Togashi, Young Hak Kim, Yukimasa Hatachi, Akiko Fukuhara, Kaoru Irisa, Yuichi Sakamori & Michiaki Mishima

  2. Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Japan

    Shiro Fujita

Authors
  1. Katsuhiro Masago
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shiro Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tadashi Mio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yosuke Togashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Young Hak Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yukimasa Hatachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akiko Fukuhara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kaoru Irisa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yuichi Sakamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michiaki Mishima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katsuhiro Masago.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Masago, K., Fujita, S., Mio, T. et al. Clinical significance of the ratio between the alpha 2 plasmin inhibitor–plasmin complex and the thrombin–antithrombin complex in advanced non-small cell lung cancer. Med Oncol 28, 351–356 (2011). https://doi.org/10.1007/s12032-010-9454-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9454-y

Keywords

Search

Navigation